机构:[1]Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Nan Si Huan Xi Lu 119, Fengtai District, Beijing 100070, China.首都医科大学附属天坛医院[2]Department of Hematology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China[3]Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.首都医科大学附属天坛医院[4]Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.神经科系统神经外科首都医科大学宣武医院[5]Department of Hematology, Chinese PLA General Hospital, Beijing, China.[6]Neuroimaging Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.首都医科大学附属天坛医院[7]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.首都医科大学附属天坛医院
This study was supported by the Capital’s Funds for Health Improvement
and Research (2020-2-2049) and the Natural Science Foundation of Beijing
Municipality (7172071).
第一作者机构:[1]Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Nan Si Huan Xi Lu 119, Fengtai District, Beijing 100070, China.[2]Department of Hematology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
通讯作者:
推荐引用方式(GB/T 7714):
Zhang Xiaowei,Wu Yuchen,Sun Xuefei,et al.The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.[J].BMC CANCER.2022,22(1):doi:10.1186/s12885-022-09275-z.
APA:
Zhang Xiaowei,Wu Yuchen,Sun Xuefei,Cui Qu,Bai Xueyan...&Liu Yuanbo.(2022).The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis..BMC CANCER,22,(1)
MLA:
Zhang Xiaowei,et al."The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.".BMC CANCER 22..1(2022)